Hearing Loss During Osteosarcoma Chemotherapy

Objective To raise awareness of the growing list of non–platinum-based chemo- and immunotherapeutic agents that have been associated with ototoxicity and to introduce the possible mechanism of ototoxicity of these agents. Data Sources PubMed, Embase, and Web of Science. Review Methods A systematic review was performed following the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-analyses). PubMed, Embase, and Web of Science databases were searched for published reports of ototoxicity from non–platinum-based chemo- and immunotherapeutic agents in adult and pediatric patients. Therapies that utilized any platinum-based agent were excluded. Conclusions Ototoxicity from non–platinum-based chemo- and immunotherapies is an evolving problem. There were 54 reports—39 case reports and 15 cohort studies—documenting ototoxicity from 7 agents/combination therapies. Of these reports, 37 (69%) were published within the last 15 years (after 2005). No recovery of hearing was documented in 21 of 56 cases (38%). Pretreatment audiograms were uncommon (19/54 studies, 35%), despite documented ototoxic associations. Implications for Practice There is a growing number of novel, ototoxic, non–platinum-based chemo- and immunotherapeutic agents with various potential mechanisms of action. Otolaryngologists will need to prioritize awareness of these agents. This growing list of agents, many of which have reversible effects, suggest a need for standardized ototoxicity monitor protocols so that appropriate and timely management options can be implemented.

show abstract

“… a All patients were adults except for those in Robert et al 41 and Kalcioglu et al, 54 which were pediatric 54 …”

Section: Methodsmentioning

confidence: 99%

Ototoxicity Review: A Growing Number of Non–Platinum‐Based Chemo‐ and Immunotherapies

Naples

Rice-Narusch

Watson

et al. 2022

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

show abstract

“…And these survival rates appear to reach a plateau phase for the past 20 years. Furthermore, in some cases, the unwanted side effects of chemotherapy may result in treatment interruption or dose reduction, even in relatively young patients [3]. Therefore, there is an imperative to develop more effective drugs against OS.…”

Section: Introductionmentioning

confidence: 99%

The Proapoptotic Effect of Formononetin in Human Osteosarcoma Cells: Involvement of Inactivation of ERK and Akt Pathways

Liu¹,

He²,

Chen³

et al. 2014

Cell Physiol Biochem

View full text Add to dashboard Cite

Background: Previous studies have shown that some phytoestrogens inhibits proliferation and induces apoptosis in estrogen-dependent cancers via estrogen receptor (ER)-mediated signaling pathway. In view of the expression of ER in human osteosarcoma cells, the purpose of this study is to investigate whether formononetin and calycosin, two of the major isoflavones in Radix astragali, could also elicit anti-tumor activity against osteosarcoma, along with the underlying mechanism. Methods: Human osteosarcoma cells U2OS were respectively treated with various concentrations of formononetin or calycosin. Cell proliferation was determined by MTT assay, while apoptosis by flow cytometry. Next, the expression levels of apoptosis-related genes ERK, Akt, Bcl-2, Bax and caspase-3 were quantified by real-time PCR and Western blotting. Results: Formononetin exhibited higher anti-proliferative activities toward human osteosarcoma cells U2OS, when compared with calycosin. Therefore, U2OS cells were then respectively treated with various concentrations of formononetin, in order to elucidate the isoflavones-related signaling pathway. It was found that formononetin dose-dependently triggered apoptosis of U2OS cells in vitro. Furthermore, treatment of formononetin led to significant inactivation of ERK and Akt, followed by downregulation of Bcl-2, upregulation of Bax and finally increased expression of caspase-3. Conclusion: Formononetin is more effective than calycosin at promoting cell death of U2OS cells by induction of apoptosis, which is mediated by inactivation of ERK and Akt signaling pathways. Thus isoflavones, especially formononetin, may be useful as anti-cancer drugs for osteosarcoma through their apoptosis-inducing effects.

show abstract

Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy

Leung

Papademetriou

Chang

et al. 2016

Curr Treat Options Gastro

View full text Add to dashboard Cite

As new and effective novel therapies in inflammatory bowel disease (IBD) become available, patients are living longer with advancing age and are at increased risk for malignancy. The management of IBD and malignancy involves multiple combinations of chemotherapy agents and IBD drugs, with the potential for interactions between these therapies. Interactions may either potentiate the effectiveness of drug class or exacerbate their common side effects. In this review article, we present a guide on studied interactions between IBD therapies and chemotherapy agents, specifically those of colorectal cancer, breast cancer, non-Hodgkin's lymphoma, and melanoma. The pharmacology and pharmocokinetics of each IBD drug will be discussed. Then, the IBD drug and chemotherapy interactions are summarized in table format. This guide will provide a quick reference to guide clinicians with this challenging management of two disease processes.

show abstract

Hearing Loss During Osteosarcoma Chemotherapy

Cited by 6 publications

References 6 publications

Ototoxicity Review: A Growing Number of Non–Platinum‐Based Chemo‐ and Immunotherapies

Ototoxicity Review: A Growing Number of Non–Platinum‐Based Chemo‐ and Immunotherapies

The Proapoptotic Effect of Formononetin in Human Osteosarcoma Cells: Involvement of Inactivation of ERK and Akt Pathways

Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy

Contact Info

Product

Resources

About